top of page

FDA approves Lembaz as first treatment shown to extend survival in infantile-onset Niemann-Pick disease type C

Writer: nuaxia
nuaxia
3 hours ago
2 min read

The FDA has approved Lembaz for patients with infantile-onset Niemann–Pick disease type C, following evidence of extended survival in a rare and progressive neurological disorder.


On 17 November 2026, the US Food and Drug Administration approved Lembaz (adrabetadex) to reduce the risk of death in adults and children weighing at least 7 kg whose neurological symptoms of Niemann–Pick disease type C began before the age of six.


FDA-reviewed evidence involving 36 treated patients showed a 55% reduction in the risk of death compared with matched external controls, with median survival of 8.5 versus 4.9 years; the intrathecal medicine carries a boxed warning for hearing impairment, including permanent hearing loss, and is the first NPC treatment shown to extend survival rather than the first medicine approved for the disease overall.

Field

Content

Company

Not specified in supplied source summary

Medicine

Lembaz (adrabetadex)

Regulatory Authority

US Food and Drug Administration

Approval Date

17 November 2026

Approval Type

New treatment approval

Therapeutic Area

Rare neurological diseases

Indication

Infantile-onset Niemann–Pick disease type C

Eligible Patients

Adults and children weighing at least 7 kg with neurological symptom onset before age six

Treatment Objective

Reduce the risk of death

Administration

Intrathecal

Clinical Evidence

FDA-reviewed evidence from 36 treated patients compared with matched external controls

Survival Benefit

55% reduction in risk of death versus matched external controls

Median Survival

8.5 years with treatment versus 4.9 years in matched external controls

Key Safety Warning

Boxed warning for hearing impairment including permanent hearing loss

Regulatory Significance

First NPC treatment shown to extend survival; not the first NPC medicine approved overall

Clinical Implications

Provides a survival-focused treatment option for eligible patients with early-onset neurological disease

Primary Source

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer


Discover how nuaxia can support your next medical education initiative:

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page